A Bonjoch

Summary

Affiliation: Lluita contra la SIDA Foundation
Country: Spain

Publications

  1. doi request reprint Switching the third drug of antiretroviral therapy to maraviroc in aviraemic subjects: a pilot, prospective, randomized clinical trial
    Anna Bonjoch
    HIV Unit and Fundació Lluita contra la SIDA, Hospital Universitari Germans Trias i Pujol, Barcelona, Catalonia, Spain
    J Antimicrob Chemother 68:1382-7. 2013
  2. doi request reprint High rate of reversibility of renal damage in a cohort of HIV-infected patients receiving tenofovir-containing antiretroviral therapy
    Anna Bonjoch
    Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Autonomous University, Barcelona, Spain
    Antiviral Res 96:65-9. 2012
  3. doi request reprint High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study
    Anna Bonjoch
    Lluita contra la SIDA Foundation, University Hospital Germans Trias, Barcelona, Spain
    AIDS 24:2827-33. 2010
  4. doi request reprint Validation of estimated renal function measurements compared with the isotopic glomerular filtration rate in an HIV-infected cohort
    Anna Bonjoch
    University Hospital Germans Trias, Barcelona, Spain
    Antiviral Res 88:347-54. 2010
  5. doi request reprint Transient treatment exclusively containing nucleoside analogue reverse transcriptase inhibitors in highly antiretroviral-experienced patients preserves viral benefit when a fully active therapy was initiated
    A Bonjoch
    Lluita contra la SIDA Foundation, University Hospital Germans Trias i Pujol, Badalona, Spain
    HIV Clin Trials 9:387-98. 2008
  6. ncbi request reprint Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 months of follow-up
    E Negredo
    Fundació Lluita contra la Sida, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    Antivir Ther 4:23-8. 1999
  7. doi request reprint Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: a multicentre pilot study
    J M Llibre
    Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain Departament de Medicina, Universitat Autonoma de Barcelona, Barcelona, Spain corrected
    HIV Med 9:508-13. 2008
  8. ncbi request reprint High-dose saquinavir plus ritonavir: long-term efficacy in HIV-positive protease inhibitor-experienced patients and predictors of virologic response
    R Paredes
    Retrovirology Laboratory Institut de Recerca de la SIDA Caixa, Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain
    J Acquir Immune Defic Syndr 22:132-8. 1999
  9. doi request reprint Human papillomavirus 16 integration and risk factors associated in anal samples of HIV-1 infected men
    María Paz Cañadas
    Retrovirology Laboratory irsiCaixa Foundation, Barcelona, Spain
    Sex Transm Dis 37:311-5. 2010
  10. ncbi request reprint Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study
    L Ruiz
    IrsiCaixa Foundation, Retrovirology Laboratory and HIV Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    J Acquir Immune Defic Syndr 27:229-36. 2001

Collaborators

Detail Information

Publications14

  1. doi request reprint Switching the third drug of antiretroviral therapy to maraviroc in aviraemic subjects: a pilot, prospective, randomized clinical trial
    Anna Bonjoch
    HIV Unit and Fundació Lluita contra la SIDA, Hospital Universitari Germans Trias i Pujol, Barcelona, Catalonia, Spain
    J Antimicrob Chemother 68:1382-7. 2013
    ..To evaluate the safety and efficacy of switching the third drug of antiretroviral treatment to maraviroc in aviraemic subjects infected with R5 HIV...
  2. doi request reprint High rate of reversibility of renal damage in a cohort of HIV-infected patients receiving tenofovir-containing antiretroviral therapy
    Anna Bonjoch
    Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Autonomous University, Barcelona, Spain
    Antiviral Res 96:65-9. 2012
    ....
  3. doi request reprint High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study
    Anna Bonjoch
    Lluita contra la SIDA Foundation, University Hospital Germans Trias, Barcelona, Spain
    AIDS 24:2827-33. 2010
    ..Low bone mineral density (BMD) is an emerging metabolic condition in HIV-infected patients; however, data on progression of this disease are scarce...
  4. doi request reprint Validation of estimated renal function measurements compared with the isotopic glomerular filtration rate in an HIV-infected cohort
    Anna Bonjoch
    University Hospital Germans Trias, Barcelona, Spain
    Antiviral Res 88:347-54. 2010
    ....
  5. doi request reprint Transient treatment exclusively containing nucleoside analogue reverse transcriptase inhibitors in highly antiretroviral-experienced patients preserves viral benefit when a fully active therapy was initiated
    A Bonjoch
    Lluita contra la SIDA Foundation, University Hospital Germans Trias i Pujol, Badalona, Spain
    HIV Clin Trials 9:387-98. 2008
    ..We determined whether coformulated zidovudine/lamivudine/abacavir plus tenofovir could maintain immune status in comparison with a genotype-guided salvage regimen in highly pretreated patients...
  6. ncbi request reprint Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 months of follow-up
    E Negredo
    Fundació Lluita contra la Sida, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    Antivir Ther 4:23-8. 1999
    ..Maintenance of viral suppression was equivalent in both treatment groups. Additional data with longer follow-up are needed to confirm these results...
  7. doi request reprint Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: a multicentre pilot study
    J M Llibre
    Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain Departament de Medicina, Universitat Autonoma de Barcelona, Barcelona, Spain corrected
    HIV Med 9:508-13. 2008
    ..To evaluate the safety, immunological outcome and HIV-1 evolution in the reverse transcriptase (RT) in patients with multidrug resistance receiving zidovudine/lamivudine/abacavir (TZV) plus tenofovir (TDF)...
  8. ncbi request reprint High-dose saquinavir plus ritonavir: long-term efficacy in HIV-positive protease inhibitor-experienced patients and predictors of virologic response
    R Paredes
    Retrovirology Laboratory Institut de Recerca de la SIDA Caixa, Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain
    J Acquir Immune Defic Syndr 22:132-8. 1999
    ..This therapeutic efficacy is strongly implemented by a switch at the lower HIV-1 RNA levels...
  9. doi request reprint Human papillomavirus 16 integration and risk factors associated in anal samples of HIV-1 infected men
    María Paz Cañadas
    Retrovirology Laboratory irsiCaixa Foundation, Barcelona, Spain
    Sex Transm Dis 37:311-5. 2010
    ..PATIENTS METHODS: This cross-sectional study included 269 HIV-infected males. Detection and typing of HPV-infection was done by multiplex PCR, and integration of HPV-16 by real-time PCR...
  10. ncbi request reprint Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study
    L Ruiz
    IrsiCaixa Foundation, Retrovirology Laboratory and HIV Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
    J Acquir Immune Defic Syndr 27:229-36. 2001
    ..Small nonrandomized studies have suggested a beneficial role of PI-sparing regimens on lipodystrophy...
  11. ncbi request reprint Prospective randomized two-Arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy
    A Tuldrá
    HIV Unit, Fundació Lluita SIDA and IrsiCaixa Retrovirology Laboratory, Germans Trias i Pujol University Hospital, Badalona, Spain
    J Acquir Immune Defic Syndr 25:221-8. 2000
    ..Interventions to ensure a high level of adherence during a relatively long-term period of therapy are necessary...
  12. doi request reprint Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA)
    Eugenia Negredo
    Lluita contra la SIDA Foundation, Barcelona, Spain
    Clin Infect Dis 49:892-900. 2009
    ..This study aimed to evaluate in vivo the effects of NRTI withdrawal on mitochondrial parameters and body fat distribution...
  13. doi request reprint HIV-1 infected patients older than 50 years. PISCIS cohort study
    G Navarro
    Corporación Sanitaria Parc Taulí, Sabadell, Barcelona, Spain
    J Infect 57:64-71. 2008
    ..The aim of this study is to characterize the ways in which older HIV-infected people differ from younger HIV-infected people...
  14. doi request reprint Epidemiological data of different human papillomavirus genotypes in cervical specimens of HIV-1-infected women without history of cervical pathology
    Sebastian Videla
    Lluita contra la SIDA Foundation, Spain
    J Acquir Immune Defic Syndr 50:168-75. 2009
    ..To study the epidemiology of different human papillomavirus (HPV) genotypes in cervical samples of HIV-1-infected women with normal Papanicolau smears...